• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4657933)   Today's Articles (270)   Subscriber (51258)
For: Zhang J, Liang W, Liang H, Wang X, He J. Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses. Ann Transl Med 2019;7:244. [PMID: 31317014 DOI: 10.21037/atm.2019.04.72] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Number Cited by Other Article(s)
1
da Costa AABA, Souza RP, Pandolfi NC, de Souza Castro F, Baiocchi G, Guimarães APG. Regarding "Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18". Gynecol Oncol 2024;189:109-110. [PMID: 39084160 DOI: 10.1016/j.ygyno.2024.07.680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2024] [Accepted: 07/24/2024] [Indexed: 08/02/2024]
2
Shahnam A, Hitchen N, Nindra U, Manoharan S, Desai J, Tran B, Solomon B, Luen SJ, Hui R, Hopkins AM, Sorich MJ. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer 2024;198:113503. [PMID: 38134560 DOI: 10.1016/j.ejca.2023.113503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/06/2023] [Accepted: 12/14/2023] [Indexed: 12/24/2023]
3
Shahnam A, Nindra U, Desai J, Hui R, Buyse M, Hopkins AM, Sorich MJ. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis. J Natl Cancer Inst 2023;115:1475-1482. [PMID: 37540222 DOI: 10.1093/jnci/djad152] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 07/06/2023] [Accepted: 07/31/2023] [Indexed: 08/05/2023]  Open
4
Yanagisawa T, Quhal F, Kawada T, Bekku K, Laukhtina E, Rajwa P, Deimling MV, Chlosta M, Pradere B, Karakiewicz PI, Mori K, Kimura T, Schmidinger M, Shariat SF. Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. Immunotherapy 2023;15:1309-1322. [PMID: 37694583 DOI: 10.2217/imt-2023-0039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]  Open
5
Saad ED, Coart E, Deltuvaite-Thomas V, Garcia-Barrado L, Burzykowski T, Buyse M. Trial Design for Cancer Immunotherapy: A Methodological Toolkit. Cancers (Basel) 2023;15:4669. [PMID: 37760636 PMCID: PMC10527464 DOI: 10.3390/cancers15184669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 08/12/2023] [Accepted: 09/05/2023] [Indexed: 09/29/2023]  Open
6
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open 2023;8:100787. [PMID: 36842300 PMCID: PMC9984799 DOI: 10.1016/j.esmoop.2023.100787] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 12/03/2022] [Accepted: 01/04/2023] [Indexed: 02/28/2023]  Open
7
Huang H, Tang Y, Yu Y, Yu A, Wu D, Fang H, Wang S, Sun C, Wang X, Fan Q, Fang Y, Tang Q, Jiang N, Du J, Miao H, Bai Y, Ma P, Xing S, Cui D, Miao S, Jiang Y, Zhu J, Zhu Q, Leng Y, Guo LW, Liao S, Shao Y, Song Y, Liu Z, Hong M, Luo S, Xu B, Lan G, Li N. The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges. THE LANCET REGIONAL HEALTH - WESTERN PACIFIC 2023;31:100624. [DOI: 10.1016/j.lanwpc.2022.100624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/20/2022] [Accepted: 10/13/2022] [Indexed: 11/19/2022]
8
Ghali F, Zhao Y, Patel D, Jewell T, Yu EY, Grivas P, Montgomery RB, Gore JL, Etzioni RB, Wright JL. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. EUR UROL SUPPL 2022;47:58-64. [PMID: 36601043 PMCID: PMC9806712 DOI: 10.1016/j.euros.2022.11.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2022] [Indexed: 12/16/2022]  Open
9
Hua T, Gao Y, Zhang R, Wei Y, Chen F. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer 2022;22:1022. [PMID: 36171546 PMCID: PMC9520950 DOI: 10.1186/s12885-022-10046-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Accepted: 08/31/2022] [Indexed: 11/10/2022]  Open
10
Goring S, Varol N, Waser N, Popoff E, Lozano-Ortega G, Lee A, Yuan Y, Eccles L, Tran P, Penrod JR. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis. Lung Cancer 2022;170:122-132. [PMID: 35767923 DOI: 10.1016/j.lungcan.2022.06.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 06/10/2022] [Accepted: 06/13/2022] [Indexed: 01/12/2023]
11
Dehbi HM, Embleton-Thirsk A, McCaw ZR. Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence. Stat Med 2022;41:4022-4033. [PMID: 35688463 PMCID: PMC9544500 DOI: 10.1002/sim.9490] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 05/16/2022] [Accepted: 05/23/2022] [Indexed: 11/30/2022]
12
Wildsmith S, Ye J, Franks A, Melillo G, Armstrong J, Whiteley J, Schnittker K, Lian F, Roland B, Sabalos C, Ahmadi P, Fayette J, Even C, Mesía R, Siu LL, Zandberg DP, Walker J. Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. CANCER RESEARCH COMMUNICATIONS 2022;2:39-48. [PMID: 36860696 PMCID: PMC9973403 DOI: 10.1158/2767-9764.crc-21-0032] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 11/17/2021] [Accepted: 12/21/2021] [Indexed: 06/18/2023]
13
Kojadinovic A, Laderian B, Mundi PS. Targeting TRK: A fast-tracked application of precision oncology and future directions. Crit Rev Oncol Hematol 2021;165:103451. [PMID: 34389458 DOI: 10.1016/j.critrevonc.2021.103451] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2021] [Revised: 07/27/2021] [Accepted: 08/08/2021] [Indexed: 12/14/2022]  Open
14
He LN, Zhang X, Li H, Chen T, Chen C, Zhou Y, Lin Z, Du W, Fang W, Yang Y, Huang Y, Zhao H, Hong S, Zhang L. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy. Front Oncol 2021;10:621329. [PMID: 33552993 PMCID: PMC7863973 DOI: 10.3389/fonc.2020.621329] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 11/27/2020] [Indexed: 12/13/2022]  Open
15
Götte H, Xiong J, Kirchner M, Demirtas H, Kieser M. Optimal decision‐making in oncology development programs based on probability of success for phase III utilizing phase II / III data on response and overall survival. Pharm Stat 2020;19:861-881. [DOI: 10.1002/pst.2042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 05/18/2020] [Accepted: 05/27/2020] [Indexed: 11/10/2022]
16
Endpoint surrogacy in oncology Phase 3 randomised controlled trials. Br J Cancer 2020;123:333-334. [PMID: 32451466 PMCID: PMC7403397 DOI: 10.1038/s41416-020-0896-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2020] [Accepted: 05/01/2020] [Indexed: 12/17/2022]  Open
17
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer 2020;122:1707-1714. [PMID: 32214230 PMCID: PMC7250908 DOI: 10.1038/s41416-020-0805-y] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 01/16/2020] [Accepted: 02/28/2020] [Indexed: 02/08/2023]  Open
18
Seidman AD, Maues J, Tomlin T, Bhatnagar V, Beaver JA. The Evolution of Clinical Trials in Metastatic Breast Cancer: Design Features and Endpoints That Matter. Am Soc Clin Oncol Educ Book 2020;40:1-11. [PMID: 32223668 DOI: 10.1200/edbk_280451] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA